Cancer Therapy AdvisorEpkinly Approved for Relapsed, Refractory Diffuse Large B-Cell Lymphoma

Approval was based on the phase 2 EPCORE NHL-1 trial, featuring an efficacy population of 148 patients.

Recent FDA approval of Epkinly (epcoritamab-bysp) introduces a new therapeutic option for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma, promising a significant shift in current treatment practices.

Key Points:

• The FDA has granted accelerated approval to Epkinly for adults with relapsed or refractory DLBCL and high-grade B-cell lymphoma after 2+ lines of systemic therapy.
• Epcoritamab is an IgG1-bispecific antibody targeting CD3 on T cells and CD20 on B cells, thus promoting T-cell-mediated killing of CD20-positive cells.
• Study results indicated an overall response rate of 61%, with 38% of patients achieving complete response and 23% achieving partial response.
• The median duration of response was 15.6 months.

Additional Points:

• Reported adverse reactions included cytokine release syndrome (CRS), fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea.
• The most common grade 3-4 laboratory abnormalities were decreased lymphocyte count, neutrophil count, white blood cell count, hemoglobin, and platelets.
• A boxed warning for Epkinly highlights potential for CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), which occurred in 51% and 6% of study participants, respectively.

Conclusion:

• Epkinly, now approved for treating relapsed or refractory DLBCL and high-grade B-cell lymphoma, shows considerable promise, but healthcare professionals must be aware of the potential severe reactions such as CRS and ICANS.

Hematology/Oncology Latest Posts

• Major Lawsuit Against Cancer Charity Offers Reminder to OncologistsApril 29, 2024
• Oncology Fraud: Authorities Now Better Able to Detect Billing AbusesApril 29, 2024
• Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD ProphylaxisApril 29, 2024
• Oncology Leader Calls for Antitrust Probe: “We’re Talking About People’s Lives”April 15, 2024
• Secondary Hypertrophic OsteoarthropathyApril 10, 2024

Did You Know?
DLBCL is the most common type of non-Hodgkin lymphoma in adults, accounting for about 25% of all non-Hodgkin lymphoma cases.